Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 16/20 | 0.72 |
| ▸ | SLC6A5 | Q9Y345 | 5/20 | 0.64 |
| ▸ | IDE | P14735 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.52 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4939733 | 0.91 | SLC6A9 (0.75) | SLC6A9SLC6A5IDEUSP2LMNA | |
| SCHEMBL4934646 | 0.91 | SLC6A9 (0.72) | SLC6A9SLC6A5IDELMNACNR1 | |
| SCHEMBL13687970 | 0.88 | SLC6A9 (0.80) | SLC6A9SLC6A5IDEGPR55 | |
| SCHEMBL4936736 | 0.88 | SLC6A9 (0.73) | SLC6A9SLC6A5IDECNR1GPR55 | |
| SCHEMBL4930244 | 0.88 | SLC6A9 (0.82) | SLC6A9SLC6A5IDEGPR55 | |
| SCHEMBL4936692 | 0.87 | SLC6A9 (0.77) | SLC6A9SLC6A5GPR55 | |
| SCHEMBL4938614 | 0.87 | SLC6A9 (0.67) | SLC6A9SLC6A5IDE | |
| SCHEMBL4938266 | 0.86 | SLC6A9 (0.77) | SLC6A9SLC6A5IDE | |
| SCHEMBL4933893 | 0.86 | SLC6A9 (0.67) | SLC6A9SLC6A5CNR1GPR55MAPT | |
| SCHEMBL3920703 | 0.86 | SLC6A9 (0.85) | SLC6A9SLC6A5GPR55 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090822-A1 | Piperazine Derivatives As Glyt 1 Inhibitors | GLAXO GROUP LIMITED | 2008-04-17 | — | — | US | disclosed |
| US-20080090822-A1 | Piperazine Derivatives As Glyt 1 Inhibitors | GLAXO GROUP LIMITED | 2008-04-17 | — | — | US | disclosed |
| US-20080090822-A1 | Piperazine Derivatives As Glyt 1 Inhibitors | GLAXO GROUP LIMITED | 2008-04-17 | — | — | US | disclosed |
| WO-2006094843-A1 | PIPERAZINE DERIVATIVES AS GLYT1 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090822-A1 | Piperazine Derivatives As Glyt 1 Inhibitors | SLC6A7, SLC6A5, SLC1A2 | SLC6A9 22/4885SLC6A5 2/4885IDE 3230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.